Fermentation Products From Armillaria Mellea Effect The Migrabolic Rats On Metabolic Disorders Of Physiological And Biochemical

In this study, we do a variety of experiments on migraine rat model to analyze pharmacology andtoxicology of Armillaria fermentation products. We studied the impact of Armillaria fungus fermentationproducts to rats’ neurochemical metabolic disorders by observing the changes of β-EP, CGRP, NO, NOS inblood and brainstem of rats, to investigate the mechanism and toxicological of Armillaria fungusfermentation products to rats’ neurochemical metabolic disorders.Method: Study on nitroglycerin-type migraine in a rat model and as an indicator to the rats brainstem and its neck vein, observing their content of β—EP、CGRP、NO、NOS respectively. By toxicologicalexperiment, rats were fed fermentation products Armillaria on the equivalent of200times the clinical dose,after that,we observe its reaction. The main contents and results are as follows:①Through determining the NO、NOS in rat plasma of experimental model, the results show thatthe model group plasma NO, NOS levels increased, and there are significant differences in the saline groupwhich as comparison(P <0.01);in Armillaria concentration group, the high concentration group, westernmedicine group, the content of NO, NOS in plasma decreased, and there is a significant difference (P <0.01)compared with the model group, had no difference with the saline group. Experiments show that Armillariafermentation products can inhibit the content of NO, NOS in blood caused by nitroglycerin (NTG).②Through determining the β—EP in rat plasma and brainstem of experimental model, the resultsshow that the content of β—EP in rat plasma and brainstem of model group have reduced; the content ofβ—EP in plasma and brainstem on Armillaria concentration group, the high concentration group increased,and there is a significant difference (P <0.01P＜0.05) compared with the model group, had no differencewith the saline group.The content of β—EP in plasma on western medicine group increased, and there is asignificant difference (P <0.01) compared with the model group, no difference with the saline group.Armillaria fermentation products can inhibit the content of β-EP in blood and brainstem caused bynitroglycerin (NTG).③Through determining the NO、NOS in rat brainstem of experimental model, the results showthat the model group brainstem NO, NOS levels increased, and there are significant differences in the saline group which as comparison(P <0.01);in Armillaria concentration group, the high concentration group,western medicine group, the content of NO, NOS in brainstem decreased, and there is a significantdifference (P <0.01) compared with the model group, had no difference with the saline group. Experimentsshow that Armillaria fermentation products can inhibit the content of NO, NOS in brainstem caused bynitroglycerin (NTG).④By determining the CGRP in rat plasma and brainstem of experimental model, the results showthat the model group brainstem CGRP levels increased, and there are significant differences in the salinegroup which as comparison(P <0.01);in Armillaria concentration group, the high concentration group,western medicine group, the content of CGRP in plasma and brainstem decreased, and there is a significantdifference (P <0.01) compared with the model group, no difference with the saline group. Experimentsshow that Armillaria fermentation products can inhibit the content of CGRP in blood and brainstem causedby nitroglycerin (NTG).⑤By toxicological experiment, rats were fed to Armillaria fermentation products (200timesdosage clinical). Administration within a week without adverse phenomena, no deaths occurred, weightgain is normal growth before and after the experimental. Armillaria fermentation products showed nosignificant side effects.